We are live on ! Find out more
ARTL icon

Artelo Biosciences
ARTL

1 hedge funds and large institutions have $38K invested in Artelo Biosciences in 2019 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.15% less ownership

Funds ownership: 0.57% → 0.42% (-0.15%)

12% less capital invested

Capital invested by funds: $43K → $38K (-$5K)

50% less funds holding

Funds holding: 2 → 1 (-1)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
1
Holders Change
-1
Holders Change %
-50%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$8K
2
TRCT
Tower Research Capital (TRC)
New York
-$1K

ARTL Hedge Fund Activity: Q4 2019 in Review

1 of the 5,093 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q4 2019, worth a combined $38K — down 12% from $43K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of ARTL and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was UBS Group, exiting entirely with an estimated $8K sold.

  • 1 institutional investor held Artelo Biosciences (ARTL) as of Q4 2019, down from 2 in Q3 2019.
  • Funds reported $38K of Artelo Biosciences stock for Q4 2019, down 12% quarter-over-quarter.
  • 0 funds opened new Artelo Biosciences positions in Q4 2019 and 1 closed out, a net change of -1 holder.
  • The largest Artelo Biosciences seller in Q4 2019 was UBS Group, an estimated $8K sold.

Based on aggregated 13F filings for Q4 2019.